UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 14, 2016

IMPRIMIS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Delaware	**001-35814**	**45-0567010**
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

12264 El Camino Real, Suite 350 **San Diego, CA** (Address of principal executive offices)	**92130** (Zip Code)

Registrant's telephone number, including area code: **(858) 704-4040**

N/A
(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On November 14, 2016, Imprimis Pharmaceuticals, Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2016. The press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 7.01 Regulation FD Disclosure

Attached as Exhibit 99.2 to this Item 7.01 is a presentation that is being used by the management of the Company at investor conferences and at meetings describing the Company.

The information furnished under this Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and 7.01, including Exhibit 99.1 and 99.2, shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent it is specifically incorporated by reference but regardless of any general incorporation language in such filing.

The information furnished under this Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed to constitute an admission that such information or exhibit is required to be furnished pursuant to Regulation FD or that such information or exhibit contains material information that is not otherwise publicly available. In addition, the Company does not assume any obligation to update such information or exhibit in the future.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

99.1 Press release dated November 14, 2016 issued by Imprimis Pharmaceuticals, Inc.

99.2 Imprimis Pharmaceuticals, Inc. presentation dated November 2016

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IMPRIMIS PHARMACEUTICALS, INC.

Dated: November 15, 2016

By: */s/ Andrew R. Boll*
Name: Andrew R. Boll
Title: Chief Financial Officer

EXHIBIT INDEX

99.1	Press release date November 14, 2016 issued by Imprimis Pharmaceuticals, Inc.
99.2	Imprimis Pharmaceuticals, Inc. presentation dated November 2016

Imprimis Pharmaceuticals Announces Third Quarter 2016 Financial Results

San Diego, Calif. – November 14, 2016 — Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the production and dispensing of high quality innovative compounded medications, today reported financial results for the third quarter 2016.

Recent Highlights:

- Revenue of $4.9 million in the third quarter of 2016, up 81% compared to revenue of $2.7 million reported in the same quarter a year ago
- Recorded cash gains from insurance claim for business interruption and property loss at Texas facility of $861,000 ($818,000 for lost expected profits during the period)
- Ophthalmology-related revenue of $3.0 million in the third quarter 2016, up 254% year over year
- Net loss of $3.9 million reported in third quarter of 2016 compared to $4.0 million reported the same quarter of the prior year
- Gross margin of 52% for the third quarter 2016
- Streamlined operations and implemented programs to reduce expected cash based expenses by nearly $3 million annually

“Throughout the third quarter, we continued to see growing demand for our formulations, especially in the ophthalmology sector, which grew sequentially despite typically slower summer months. We also saw increasing adoption for many of our other formulations as we drove awareness and improved access. In addition to making meaningful progress in expanding our Imprimis Cares® portfolio, we were successful in growing relationships with key partners, payors and pharmacy benefit managers (PBMs),” said Mark L. Baum, CEO of Imprimis. “Revenues in the quarter were impacted by constraints in our drug production infrastructure, however I am confident recent actions taken to streamline our operations and maximize efficiencies will accelerate near-term profitability goals while ensuring a stable platform for continued long-term growth. Our New Jersey facility, which we recently registered with the FDA as an outsourcing facility, is expected to play an important role as we continue to grow our customer network and expand into new therapeutic markets.”

Recent Commercialization and Corporate Developments

- Entered into agreement with the specialty pharmacy division of one of the nation’s leading PBMs to supply Imprimis’ complete formulary through its national network of specialty pharmacies.
- Introduced compounded EDTA calcium disodium injection, a significantly lower-cost therapeutic alternative to Valeant’s Calcium Disodium Versenate for the stabilization and treatment of lead poisoning.
- Enhanced Imprimis Cares® formulary, including plans to introduce a lower-cost compounded alternative to the EpiPen® for life-threatening allergic reactions.

- Announced published data from large study of 922 patients (1,541 eyes) receiving Dropless Therapy following cataract surgery. The results demonstrated no cases of postoperative endophthalmitis or intraoperative complications. In nearly 92 percent of cases (n=1413/1541), supplemental medication after surgery was not required.

- Continued to see adoption of IV Free MKO Melt™ conscious sedation formulation, an alternative option to IV anesthetic for patients undergoing ocular and other surgical procedures. The formulations or variations thereof have been used in over 8,000 LASIK, cataract and other surgeries to date. The company is currently focused in the ocular surgery market but plans to expand into dental, urologic and other surgical procedure markets in the second half 2017.

- Increased adoption of Dropless Therapy® and our LessDrops® combination topical drops as these formulations continue to capture market share from large eye drop companies.

    - Estimated share of the cataract eye drop market is greater than 10%.

    - Serviced an estimated 375,000 ocular surgeries since launch in April 2014.

    - Expanded customer base with over 1,200 ophthalmologists.

    - Provided formulations for approximately 10,000 cataract and other ocular surgeries per week.

- Increased physician utilization of the MaxRx Prescriber Portal™ to over 550 users. The portal was introduced in July 2016 and allows for customer ordering and tracking ease.

ImprimisRx Pharmacy Operations

- Registered New Jersey facility with the U.S. Food and Drug Administration (FDA) as a 503B outsourcing facility. The new facility is expected to begin manufacturing as an outsourcing facility in December 2016 and dispensing medications in first quarter 2017. The state-of-the-art 8,600 square foot facility provides five additional cleanrooms, representing a tenfold increase in overall production levels.

Financial Summary

Selected highlights regarding operating results for the three and nine months ended September 30, 2016 and for the same periods in 2015 are as follows (in thousands, except per share data):

	For the three months ended September 30, 2016	For the nine months ended September 30, 2015
Total Revenues	$ 4,861	$ 2,683
Cost of Sales	2,339	1,202
Gross Profit	2,522	1,481
Selling & Marketing Expenses	1,797	1,813
General & Administrative Expenses	5,018	3,104
Research & Development Expenses	16	93
Impairment of intangible assets and goodwill	303	-
Other Income (Expense), net	762	(423)
Net Loss	**$ (3,850)**	**$ (3,952)**
Net Loss per Common Share	**$ (0.29)**	**$ (0.41)**

	For the nine months ended September 30, 2016	For the nine months ended September 30, 2015
Total Revenues	$ 14,149	$ 6,213
Cost of Sales	6,760	3,259
Gross Profit	7,389	2,954
Selling & Marketing Expenses	5,967	4,455
General & Administrative Expenses	13,355	8,327
Research & Development Expenses	138	299
Impairment of intangible assets and goodwill	303	-
Other (Expense), net	(611)	(648)
Net Loss	**$ (12,985)**	**$ (10,775)**
Net Loss per Common Share	**$ (1.05)**	**$ (1.13)**

Adjusted EBITDA

In addition to the company's results of operations determined in accordance with U.S. generally accepted accounting principles (GAAP), which are presented and discussed above, management also utilizes adjusted EBITDA, an unaudited financial measure that is not calculated in accordance with GAAP, to evaluate the company's financial results and performance and to plan and forecast future periods. Adjusted EBITDA is considered a "non-GAAP" financial measure within the meaning of Regulation G promulgated by the SEC. Management believes that this non-GAAP financial measure reflects an additional way of viewing aspects of the company's operations that, when viewed with GAAP results, provides a more complete understanding of the company's results of operations and the factors and trends affecting its business. Management believes adjusted EBITDA provides meaningful supplemental information regarding the company's performance because (i) it allows for greater transparency with respect to key metrics used by management in its financial and operational decision-making; (ii) it excludes the impact of non-cash or, when specified, non-recurring items that are not directly attributable to the company's core operating performance and that may obscure trends in the company's core operating performance; and (iii) it is used by institutional investors and the analyst community to help analyze the company's results. However, adjusted EBITDA and any other non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Further, non-GAAP financial measures used by the company and the manner in which they are calculated may differ from the non-GAAP financial measures or the calculations of the same non-GAAP financial measures used by other companies, including the company's competitors.

The company defines adjusted EBITDA as net income (loss) excluding the effects of interest, taxes, depreciation, amortization, stock-based compensation, other income (expense) and, if any and when specified, other non-recurring income or expense items. The company believes that the most directly comparable GAAP financial measure to adjusted EBITDA is net loss. Adjusted EBITDA has limitations and should not be considered as an alternative to gross profit or net loss as a measure of operating performance or to net cash provided by (used in) operating, investing or financing activities as a measure of ability to meet cash needs.

The following is a reconciliation of adjusted EBITDA, a non-GAAP measure to the most comparable GAAP measure, net loss, for the three months ended September 30, 2016 (in thousands):

	For the three months ended September 30, 2016
Net Loss	**$ (3,850)**
Stock-based compensation	879
Interest expense, net	732
Taxes	-
Depreciation	348
Amortization of intangible assets	79
Non-recurring expenses[(1)]	121
Impairment of intangible assets and goodwill	303
Other income net	(1,494)
Adjusted EBITDA	**$ (2,882)**

(1) Non-recurring expense items include one-time cost for abandonment of Texas facility lease.

Conference Call and Webcast

The company's management team will host a conference call and audio-only webcast today at 4:30 p.m. EST (1:30 p.m. PST) to discuss the financial results and recent developments. To participate in the call, please dial (877)-407-8035 for domestic callers or (201)-689-8035 for international callers. To listen to the webcast, please click here or visit the investor relations section of the Imprimis website at www.ImprimisRx.com. A replay of the call will be available until December 14, 2016. To access the replay, dial (877)-660-6853 domestically or (201)-612-7415 internationally and reference Conference ID: 13647429.

About Imprimis Pharmaceuticals

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a pharmaceutical company dedicated to producing and dispensing high quality innovative compounded medications in all 50 states. The company's unique business model drives patient access and affordability to many critical medicines. Headquartered in San Diego, California, Imprimis owns and operates three dispensing facilities located in California, New Jersey and Pennsylvania. For more information about Imprimis, please visit the corporate website at www.ImprimisRx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to make commercially available our compounded formulations and technologies in a timely manner or at all; physician interest in prescribing our formulations; risks related to our compounding pharmacy operations; our ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of our formulations; our ability to obtain intellectual property protection for our assets; our ability to accurately estimate our expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for our technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Other than drugs compounded at a registered outsourcing facility, all Imprimis compounded formulations may only be prescribed pursuant to a physician prescription for an individually identified patient consistent with federal and state laws.

###

Source: Imprimis Pharmaceuticals, Inc.

Imprimis Media Contact
Paul Rabin
paul@pascalecommunications.com
516.503.0271

Imprimis Investor Contact
Bonnie Ortega
bortega@imprimispharma.com
858.704.4587

NASDAQ: IMMY

Mark L. Baum, CEO
November 2016

High-quality, innovative medications at accessible prices.

Safe Harbor

This presentation contains express "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. Some of these risks and uncertainties include, but are not limited to: the Company's ability to make commercially available its formulations and technologies in a timely manner or at all; market acceptance of the Company's formulations and challenges related to the marketing of the Company's formulations; its ability to obtain intellectual property protection for its assets; its ability to accurately estimate its expenses and cash burn, and raise additional funds when necessary; its ability to generate profits from sales of its formulations; risks related to research and development activities; the projected size of the potential market for its technologies and formulations; unexpected data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC's web site at www.sec.gov. All forward-looking statements are qualified in their entirety by this cautionary statement. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Imprimis expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.

Prescription Drug Market is in Transition

- **Prescription Drug Market Realities**
  - Some pharma companies are abusing monopoly rights conferred by federal policy
  - Dramatic price increases for old off-patent drugs in $250M to $1B niche markets
  - Patient deductibles and out-of-pocket cost are increasing
  - 17% of all prescription drugs lack generic competition[1]
- **Imprimis Solution**
  - Work with payors and patient advocacy groups to design Imprimis Cares® formularies of lower cost compounded alternatives made with FDA-approved generic ingredients
  - Our medications are prescribed "off-label" just as >20% of all prescription drugs are[2]
  - Our model does not require FDA approval for the final medication
    - Lower cost, more efficient way to provide safe access to critical medications
  - Many of our medication formulations are patented or patent pending

imprimis PHARMACEUTICALS

[1] Guggenheim Securities
[2] Agency for Healthcare Research & Quality

Imprimis' Market Based Solution

Disrupting the $450B+ Total Drug Market[3]

50-80% payor savings; 60%+ gross margins

Proven Success

10%+ market share in large ophthalmology market

Pioneering a Solution to Drug Pricing Challenges

Significant IP

25+ patents issued and pending

Financial Fundamentals

Strong revenue growth; approaching profitability

[3] Observations on Trends in Prescription Drug Spending

Prescription for Lower Drug Prices

We use 7,800+ FDA-approved generic drugs to create *new* lower-cost, high-quality, customizable and often patentable compounded formulations

FDA-approved APIs made in FDA registered facilities according to USP monographs

Strict quality standards mandated by the Drug Quality & Security Act of 2013

Lower-cost novel compounded medications

Marketing and Distribution

- Two captive sales teams: Ophthalmology and Non-Ophthalmology
- Customers are:
  - Insurance/Managed Care
  - PBM networks
  - MDs and patients
- Headquartered in San Diego with three production facilities:
  - Irvine, CA
  - Ledgewood, NJ
  - Folcroft, PA
- Ship direct to patients and institutions in all 50 states
- No wholesalers or middlemen



Growing Payor Adoption

Pharmacy Benefit Managers (PBMs)

EXPRESS SCRIPTS®

OPTUMRx®

CVS/caremark™

Healthcare Payors and Strategic Accounts

Cataract & Laser Institute

NVISION EYE CENTERS

TRICARE®

AMSURG

KAISER PERMANENTE®

Ophthalmology Program

Ophthalmology Business Pipeline

TOPICAL EYE DROPS		LUCENTIS EYLEA	Mitosol	INTRAVENOUS SEDATION		OMIDRIA	NAMES WITHHELD
Post-cataract surgery	Post-LASIK, cataract surgery	Chronic wet age-related macular degeneration	Glaucoma surgery	Ophthalmic surgeries	Oral and urologic procedures	Cataract Surgery	Glaucoma
Dropless Therapy® Injectables	**LessDrops® Combination Topicals**	**Bevacizumab**	**Mitomycin**	**IV Free MKO Melt™ Conscious Sedation**		**Mydriatics**	**Combination Eye Drop**
$1B+[4] Est. total market (incumbent drugs)		**$2B**[5] Est. total market (incumbent drugs)	**$15M**[5] Est. total market (incumbent drugs)	**Unavailable** Est. total market (incumbent drugs)		**$1.8B**[6] Est. total market (incumbent drugs)	**$1B+**[5] Est. total market (incumbent drugs)
$400M+ IMMY Est. TAM[5]		**$80M** IMMY Est. TAM[5]	**$1M** IMMY est. TAM[5]	**$100M** IMMY Est. TAM[5]	**$400M** IMMY Est. TAM[5]	**$100M** IMMY Est. TAM[5]	**$700M** IMMY Est. TAM[5]
APR 2014 Launch	**JAN 2015** Launch	**2H 2017** Launch	**2H 2017** Launch	**MAY 2016** Launch	**1H 2017** Launch	**2H 2017** Launch	**2H 2017** Launch

imprimis PHARMACEUTICALS

[4] Andrew Chang & Co. LLC, Dropless Cataract Surgery Economic Study
[5] Imprimis Pharmaceuticals internal business data
[6] Omeros Corporation: My Top Pick For 2016, Seeking Alpha

Disruption in the Ophthalmology Market

- **Market Opportunity of $400M**:
  - 3.9M cataract surgeries in 2017[7]
  - 700,000 LASIK surgeries annually[8]
- **Standard of Care**:
  - 2-3 eye drops cost patients ~$323 per eye[4]
- **Our Solution**:
  - Patent-pending injectable and topical formulations, enabled by SSP Technology®
  - Comprised of FDA-approved generic drugs
  - Est. 10%+ market share of $1B[4] market
  - >325,000 surgeries completed by >1,200 MDs
  - Strong and growing body of peer-reviewed clinical data supports adoption[9,10]

imprimis PHARMACEUTICALS

[4] Andrew Chang & Co. LLC, Dropless Cataract Surgery Economic Study
[7] Market Scope Report
[8] Number of LASIK surgeries in the United States
[9] Fisher, B. L., & Potvin, R.
[10] Tyson, S. L., et al.

Increasing Dropless and LessDrops Adoption



Market Share Est. 10%+



IV Free™ Conscious Sedation

- Sublingual midazolam, ketamine and ondansetron "lozenge" alternative to intravenous sedation
- **Market Opportunities**:
  - 4.5M ocular surgeries[7,8]
  - 500K vasectomies[11]
  - 14M colonoscopies[12]
  - 1M+ dental procedures requiring sedation[5]
- Patients prefer sublingual to IV intervention; and staff prefer efficiency of sublingual sedation
- Consistent, predictable dosing allows for quick and easy administration

imprimis PHARMACEUTICALS

[5] Imprimis Pharmaceuticals internal business data
[7] Market Scope Report
[8] Number of LASIK surgeries in the United States
[11] Allen, Vasectomy Risks and Benefits
[12] Screening colonoscopies

Growth Strategy

Removing Friction Q1 '17

- **Currently operate as a compounding pharmacy**
- Regulated by 50 separate state regulatory bodies
  - Restrictions include:
    - Small batch production
    - Patient-specific prescriptions required for each order
    - Higher labor costs associated with customer service, dispensing, shipping
- **Moving to an FDA-registered 503B outsourcing facility model**
  - 80% of prescriptions expected to be dispensed from new outsourcing facility
  - Benefits include:
    - New revenue opportunities – increase in large physician practices, ambulatory surgery centers, hospitals and other large healthcare providers requiring FDA registration, cGMP quality standards and ordering ease
    - Margin expansion – increased productivity and decreased labor costs related to order intake, prescription processing, and shipping
    - Scalable growth – bigger batch sizes, greater per order quantities and larger allowable inventory amounts

Imprimis Cares® Pipeline (Non-Ophthalmology)

Thiola®	ELMIRON™	EPIPEN®	Evzio®	COMPETITOR NAMES WITHHELD
Cystinuria	Interstitial cystitis (IC)	Allergic reactions (anaphylaxis)	Opioid overdose	Withheld
Tiopronin D-R	**PPS-DR™ (Pentosan Polysulfate Sodium D-R)**	**Epinephrine Injectables**	**Naloxone**	**Hormone extended release gel**
$500M[13,14] Est. total market (incumbent drugs)	**$280M**[15,16] Est. total market (incumbent drugs)	**$1B+**[17] Est. total market (incumbent drugs)	**$1B+**[18,19] Est. total market (incumbent drugs)	**$2B**[5] Est. total market (incumbent drugs)
$160M IMMY est. TAM[5]	**$100M** IMMY Est. TAM[5]	**$500M** IMMY Est. TAM[5]	**$50M** IMMY Est. TAM[5]	**$500M** IMMY Est. TAM[5]
MAY 2016 Launch	**OCT 2015** Launch	**2H 2017** Launch	**2H 2017** Launch	**2H 2017** Launch

imprimis PHARMACEUTICALS

[5] Imprimis Pharmaceuticals internal business data
[13] Price Comparison for Thiola
[14] Retrophin Investor Presentation
[15] Price Comparison for Elmiron
[16] Trader, Seeking Alpha
[17] Koons, Bloomberg Businessweek
[18] American Society of Addiction Medicine
[19] Jacobs, Business Insider

Imprimis Cares Strategic Partners

- **Express Scripts**
  - Largest PBM in the U.S.
  - Express scripts covers 85M lives and processes over 1.3B prescriptions annually
  - Partnership announced December 2015 offering patients Imprimis' low-cost alternative to Daraprim® for $1.00 per capsule representing
  - Daraprim alternative represents an estimated payor savings of $16M since Jan 2016
- **Confidential Specialty Pharmacy of Large PBM**
  - Supply agreement signed October 2016 includes the complete Imprimis Cares® formulary
  - Specialty pharmacy division of one of the nation's largest PBMs
  - PBM covers over 65M lives in the U.S. and processes over 1B prescriptions each year
  - Clients include some of the largest private payors

Implementing Efficiencies to Grow Margins

Order Inflow:

- MaxRx Prescriber Portal™

Production:

- State-of-the-art changes to NJ and CA facilities
- Automated Filling and Labeling
- Labeling / Shipping Automation

Dispensing:

- Eliminating processing patient prescriptions

Recent Management Additions

Clayton Edwards
SVP, Pharmacy Operations
PREVIOUSLY: OPTUMRX, LIBERTY MEDICAL

Pramod Sharma
VP, Quality
PREVIOUSLY: AKORN, ALVOGEN, ALBANY MOLECULAR RESEARCH

Eric Rice
VP, Client Services
PREVIOUSLY: PHILIDOR RX, COMCAST

Sanjay Samudre
Director, Manufacturing
PREVIOUSLY: TELIGENT (IGI LABS), NOVARTIS, ENDO

Tip of the Iceberg

2014 to Present: Proving the Model

- Launched Ophthalmology business
- Acquired compounding infrastructure
- Launched Imprimis Cares formulary

2016 and Beyond: Growth and Scale

- Imprimis Cares portfolio expansion
- Large payor relationship initiations
- Market share penetration
- Production and dispensing scale (503B)
- Margin expansion

Structure and Financials

Revenue Performance & Insurance Claim



	Q4-2014	Q1-2015	Q2-2015	Q3-2015	Q4-2015	Q1-2016	Q2-2016	Q3-2016
Gross Margin	39%	36%	47%	55%	44%	49%	56%	52%
Net Loss	(2,745)	(3,093)	(3,730)	(3,952)	(5,124)	(4,496)	(4,639)	(3,850)

imprimis PHARMACEUTICALS

* Represents $818.00 gain paid for business interruption insurance claim related to lost profits for down time of Texas facility.

Capital Structure

As of September 30, 2016 (unaudited):

Common stock issued and outstanding	13,229,320
Options, weighted avg. ex. $6.26*	1,971,063
Warrants, weighted avg. ex. $5.20	240,688
Convertible note, conv. price $3.60	833,333
RSUs (time based vesting)	98,068
RSUs (market based vesting)**	1,207,500
Total diluted outstanding	17,579,972

*760,071 options excisable. Total options includes 600,000 market based options, vests at stock prices ranging from $9 to $15 and an ex. price $7.87

**Vesting requires stock prices ranging from $9 to $15

Condensed Balance Sheet - Unaudited

(in thousands of dollars)	at September 30, 2016
ASSETS	
Current assets	
Cash and restricted cash and investments	$ 2,812
Receivables, net	3.074
Prepaid expenses, inventories and other current assets	3,064
Total current assets	8,950
Goodwill and intangible assets, net	5,221
Plant, property and equipment, net	7,346
TOTAL ASSETS	**$ 21,517**
LIABILITIES AND STOCKHOLDERS' EQUITY	
Current liabilities	
Accounts payable and accrued expenses	$ 5,086
Deferred revenue and customer deposits	55
Other current liabilities	824
Total current liabilities	5,780
Long term debt and other liabilities, net of discounts	12,905
TOTAL LIABILITIES	**18,685**
TOTAL STOCKHOLDERS' EQUITY	**2,832**
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	**$ 21,517**

Company Profile

- Trading symbol: NASDAQ: IMMY
- Price per share (11-11-16): $2.66
  - Stock price range (52-week): $2.28 - $7.81
- Average daily trading volume (3 months): 50,000 shares
- Market cap: $35 million
  - Shares Outstanding: 13.2 million
  - Float: 10.4 million
- Q3-2016 Net loss: ($3,850,000)
- Q3-2016 Cash balance: $2.8 million

References and Appendix

References

1. Guggenheim Securities, LLC healthcare analyst Louise Chen
2. Agency for Healthcare Research & Quality – Off-Label Drugs: What You Need to Know. (2015, September 01). Retrieved November 08, 2016, from http://www.ahrq.gov/patients-consumers/patient-involvement/off-label-drug-usage.html
3. Observations on Trends in Prescription Drug Spending - Assistant Secretary for Planning and Evaluation. (2016, March 8). Retrieved July 14, 2016, from https://aspe.hhs.gov/sites/default/files/pdf/187586/Drugspending.pdf
4. Andrew Chang & Co LLC. Analysis of the Economic Impacts of Dropless Cataract Therapy on Medicare, Medicaid, State Governments, and Patient Costs (2015, October). Retrieved January 5, 2016, from http://www.improvedeyecare.org/CSIE_Dropless_Economic_Study.pdf.
5. Imprimis Pharmaceuticals internal business data, 2015-2016
6. H. (2015, December 16). Omeros Corporation: My Top Pick For 2016. Retrieved November 08, 2016, from http://seekingalpha.com/article/3760286-omeros-corporation-top-pick-2016
7. Market Scope, LLC, Comprehensive Report on the Global IOL Market (2013, May). Retrieved November 15, 2014.
8. Number of LASIK surgeries in the United States from 1996 to 2014. Retrieved June 3, 2016 from http://www.statista.com/statistics/271478/number-of-lasik- surgeries-in-the-us/.
9. Fisher, B. L., & Potvin, R. (2016, July 18). Transzonular vitreous injection vs a single drop compounded topical pharmaceutical regimen after cataract surgery. Retrieved October 18, 2016, from https://www.dovepress.com/transzonular-vitreous-injection-vs-a-single-drop-compounded-topical-ph-peer-reviewed-fulltext-article-OPTH
10. Tyson, S. L., et al. (2016, September 30). Clinical outcomes after injection of a compounded pharmaceutical for prophylaxis after cataract surgery: A large-scale review. Retrieved November 5, 2016, from http://journals.lww.com/co-ophthalmology/Abstract/publishahead/Clinical_outcomes_after_injection_of_a_compounded.99409.aspx
11. Allen, A. (2007). Vasectomy Risks and Benefits. Retrieved November 08, 2016, from http://www.webmd.com/men/features/vasectomy-risks-benefits
12. Screening colonoscopy: Quality, public awareness key to efficacy. (2009, August 10). Retrieved November 8, 2016, from http://www.healio.com/hematology-oncology/gastrointestinal-cancer/news/print/hemonc-today/{fd4ce3c6-efc8-4cd0-941f-8eeaa527fe6d}
13. Price Comparison for Thiola. Retrieved June 3, 2016, from http://www.goodrx.com/thiola.
14. Retrophin Investor Presentation. Retrieved September 26, 2016, from http://files.shareholder.com/downloads/AMDA-1PLA2O/2901936618x0x908705/2E29C48F-5905-47DF-BC30-670FA4E7BE5C/RTRX_Corporate_Overview_September_2016_External.pdf.

References

15. Price Comparison for Elmiron. Average cost of $650 (90 count). Retrieved June, 3, 2016 from http://www.goodrx.com/Elmiron.
16. Trader, O. (2016, September 28). Seeking Alpha -- Updating My Thesis On Aquinox After The Equity Raise. Retrieved October 18, 2016, from http://seekingalpha.com/article/4008951-updating-thesis-aquinox-equity-raise.
17. Koons, C. (2015, September 23). Bloomberg Businessweek – How Marketing Turned the EpiPen Into a Billion-Dollar Business. Retrieved November 08, 2016, from http://www.bloomberg.com/news/articles/2015-09-23/how-marketing-turned-the-epipen-into-a-billion-dollar-business
18. American Society of Addiction Medicine. Opioid Addiction 2016 Facts & Figures. (2016). Retrieved November 09, 2016, from http://www.asam.org/docs/default-source/advocacy/opioid-addiction-disease-facts-figures.pdf
19. Jacobs, H. (2016, August 01). The price of the 'antidote' to the overdose crisis is skyrocketing. Business Insider. Retrieved November 09, 2016, from http://www.businessinsider.com/price-of-naloxone-narcan-skyrocketing-2016-7


imprimis
PHARMACEUTICALS
Imprimis Pharmaceuticals
(NASDAQ: IMMY)
12264 El Camino Real, #350
San Diego, CA 92130
(858) 704-4040
www.imprimispharma.com